Comparison of Safety and Efficacy Between Silodosin Monotherapy and Silodosin with Tadalafil Add-on Therapy in Patients with Benign Prostatic Hyperplasia
Abstract
Background: In aging men, benign prostatic hyperplasia (BPH) causes bothersome lower urinary tract symptoms. Silodosin improves urinary flow by targeting alpha-1 receptors. Combining silodosin with tadalafil enhances symptom relief through synergistic smooth muscle relaxation, offering better management of BPH-related discomfort. This study aimed to compare the safety and efficacy of silodosin monotherapy with silodosin and tadalafil add-on therapy in Benign prostatic hyperplasia patients. Methods: This was a prospective observational study that was conducted in the department of Urology, Bangabandhu Sheikh Mujib Medical University (BSMMU) Bangladesh from January 2022 to December 2022. This study randomized 80 patients, age between 40-80 years with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) into two groups. Group A (40 patients) received silodosin 8 mg daily, while Group B (40 patients) received silodosin 8 mg plus tadalafil 5 mg daily. SPSS 23.0 analyzed data. Results: A comparison of IPSS scores between Group A and Group B showed significant reductions in both groups (p<0.001). Similarly, Post-Void Residual (PVR) volumes decreased significantly in both groups (p<0.001). Q-MAX scores and International Index of Erectile Function (IIEF) scores significantly improved in both groups (p<0.001). Group B demonstrated slightly greater reductions in IPSS and PVR, and greater improvements in Q-MAX and IIEF. Adverse effects were minimal, with…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.